After nearly 20 years, the Food and Drug Administration (FDA) has approved several new drugs to treat Alzheimer’s disease since 2021. These drugs, primarily antibody therapies, target toxic protein aggregates in the brain. Their approval has generated both excitement and controversy. The key question remains: Are these drugs truly effective?
Alzheimer’s disease is a neurodegenerative condition that leads to a gradual decline in memory, thinking, and daily functioning. Aging is the most significant risk factor, and with a rapidly aging population, Alzheimer’s has become a global health crisis. In 2019, 57 million people worldwide had Alzheimer’s. This number is expected to rise to 153 million by 2050, highlighting the urgent need for treatments that can slow the disease’s progression.
Despite decades of research, efforts to develop effective treatments for Alzheimer’s had largely failed until recently. Most research has focused on targeting beta-amyloid, a protein whose abnormal accumulation is believed to contribute to the disease.
In 2021, the FDA approved aducanumab, an antibody that targets amyloid-beta deposits in the brain. It was the first drug considered to modify the disease’s course. However, clinical trials for aducanumab did not consistently show improvements in cognitive function. As a result, Biogen, the company behind the drug, announced plans to eventually halt its sales.
Since then, two other anti-amyloid antibodies, lecanemab from Biogen and donanemab from Eli Lilly, have shown the ability to slow cognitive decline in early Alzheimer’s patients. Both drugs have received FDA approval and have been hailed as breakthroughs after years of unsuccessful attempts to find effective treatments.
However, some researchers are skeptical. They argue that the benefits of these drugs are modest at best and come with significant safety risks. There are also concerns about whether these treatments are cost-effective.
Dr. Dag Aarsland, a professor of old age psychiatry at King’s College London, acknowledges the challenges but emphasizes the importance of these developments. “After decades of costly trials with negative results, we finally have clear evidence that it is possible to slow disease progression,” he said. This, he believes, marks a significant breakthrough.
Similarly, Dr. Paresh Malhotra, a professor of clinical neurology at Imperial College London, pointed out that while the clinical effects of these new therapies are modest, they are the first to target a key mechanism of Alzheimer’s progression. He suggested that their introduction could accelerate the development of future treatments and transform how Alzheimer’s is treated, especially given its status as the most common cause of dementia worldwide.
In summary, while the recent approvals of lecanemab and donanemab represent progress in the fight against Alzheimer’s, they also raise important questions. The debate continues over whether these drugs offer genuine hope for patients or if their benefits are too limited to justify the risks and costs. Nonetheless, the landscape of Alzheimer’s treatment is changing, offering a glimmer of hope after decades of disappointment.
Follow us on Instagram, YouTube, Facebook, Whats App, and TikTok for latest updates.
